Latest Conference Articles

July 24th 2020, 9:35pm

International Lung Cancer Congress

Benjamin P. Levy, MD, discusses the efficacy of crizotinib (Xalkori) versus entrectinib in ROS1-rearranged lung cancer.

July 24th 2020, 6:58pm

International Lung Cancer Congress

Charu Aggarwal, MD, MPH, discusses the current state of treatment for patients with ALK-positive non–small cell lung cancer, the utility of liquid biopsy, and remaining questions that need to be addressed in the space.

July 24th 2020, 6:30pm

International Lung Cancer Congress

Although antibody-drug conjugates have yet to receive regulatory approval in the lung cancer space, several emerging agents are showing early promise in clinical trials.

July 24th 2020, 5:15pm

International Lung Cancer Congress

Clinical data shows that the TRK inhibitors entrectinib and larotrectinib induce high response rates with favorable toxicity profiles and central nervous system penetration, and are a viable treatment option for patients with advanced TRK fusion-positive cancers.

July 23rd 2020, 10:35pm

International Lung Cancer Congress

Ignacio I. Wistuba, MD, discusses the clinical importance of histological subtyping of lung cancer and additional parameters such as driver alterations, alternative methods for molecular testing, and immunotherapy-related biomarkers have strengthened the diagnostic and treatment paradigms in lung cancer.

July 23rd 2020, 10:18pm

International Lung Cancer Congress

In non–small cell lung cancer, single cell analytics, genome editing, and next-generation animal models represent just some of the modern modalities advancing translational research.

July 23rd 2020, 9:54pm

International Lung Cancer Congress

The disease-free survival benefit observed with the third-generation EGFR TKI osimertinib as an adjuvant treatment in patients with EGFR-mutant non–small cell lung cancer in the phase 3 ADAURA trial is striking.

July 23rd 2020, 9:45pm

International Lung Cancer Congress

Charu Aggarwal, MD, MPH, discusses emerging treatment approaches in ALK-positive non–small cell lung cancer.

July 23rd 2020, 9:45pm

International Lung Cancer Congress

David R. Gandara, MD, discusses the utility of tumor mutational burden in non–small cell lung cancer.

July 17th 2020, 10:42pm

International Congress on the Future of Breast Cancer East

Angela DeMichele, MD, MSCE, shares how to utilize available data with CDK4/6 inhibitors in the neoadjuvant and adjuvant settings to optimize outcomes for patients with hormone receptor–positive breast cancer.

July 17th 2020, 9:38pm

International Congress on the Future of Breast Cancer East

Terry P. Mamounas, MD, MPH, FACS, discusses common recurrence rates in breast cancer.

July 17th 2020, 9:00pm

International Congress on the Future of Breast Cancer East

The growing number of treatments within the HER2-positive breast cancer armamentarium signals a need to redefine and tailor neoadjuvant and adjuvant strategies to individual patients.

July 17th 2020, 8:50pm

International Congress on the Future of Breast Cancer East

Sara M. Tolaney, MD, MPH, discusses appropriately deescalating treatment to reduce toxicities in stage I HER2-positive breast cancer.

July 17th 2020, 8:15pm

International Congress on the Future of Breast Cancer East

The optimal sequence of therapies for patients with metastatic HER2-positive breast cancer must be an individualized one, and should be dependent on the presence and/or level of central nervous system disease.

July 13th 2020, 8:28pm

ASCO Direct Highlights

Despite the influx of novel agents that have received regulatory approval in recent years in stem cell disorders, there is still room for improvement.

July 13th 2020, 2:04pm

ASCO Direct Highlights

As part of the 2020 ASCO Direct Highlights™ webcast, Brian Rini, MD, discusses key developments in genitourinary cancers that were presented during the 2020 ASCO Virtual Scientific Program.

July 11th 2020, 9:12pm

PER® Annual Live Medical Crossfire: Hematologic Malignancies

A panel of experts in acute lymphoblastic leukemia broach the topic of innovative approaches incorporating novel agents in clinical practice.

July 11th 2020, 7:44pm

PER® Annual Live Medical Crossfire: Hematologic Malignancies

A panel of experts in acute myeloid leukemia (AML) consider potential treatment options for patients with AML

July 11th 2020, 6:45pm

PER® Annual Live Medical Crossfire: Hematologic Malignancies

A panel of experts in chronic myeloid leukemia share insight on how to optimally approach treatment based on patient characteristics.

July 11th 2020, 6:20pm

PER® Annual Live Medical Crossfire: Hematologic Malignancies

Noopur Raje, MD, discusses the current challenges faced in the multiple myeloma treatment paradigm.